Status:
RECRUITING
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
Lead Sponsor:
Regeneron Pharmaceuticals
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Detailed Description
Originally registered as OBS17104 by Sanofi; transitioned to REGN 05Jul2023. The recruitment period will be 48 months. Data will be collected during routine clinical visits approximately every three ...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
October 26 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 30 2028
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05363319
Start Date
October 26 2022
End Date
October 30 2028
Last Update
February 20 2026
Active Locations (49)
Enter a location and click search to find clinical trials sorted by distance.
1
Klinikum Klagenfurt
Klagenfurt, Carinthia, Austria, 9020
2
Salzburger Landeskliniken (SALK)
Salzburg, Austria, 5020
3
Le Groupe Hospitalier de la Region de Mulhouse et Sud Alsace, Emile Muller Hospital
Mulhouse, Alsace, France, 68100
4
Centre Hospitalier Universitaire (CHU) de Poitiers
Poitiers, Nouvelle-Aquitaine, France, 86021